Search En menu en ClientConnect
Top 5 search results See all results Advanced search
Top searches
Most visited pages


    € 25,000,000
    France : € 25,000,000
    Services : € 5,000,000
    Industry : € 20,000,000
    Signature date(s)
    29/12/2022 : € 5,000,000
    29/12/2022 : € 20,000,000
    Link to source

    Summary sheet

    Release date
    8 March 2023
    Signed | 29/12/2022
    Project name
    Promoter - financial intermediary
    Proposed EIB finance (Approximate amount)
    Total cost (Approximate amount)
    EUR 25 million
    EUR 63 million

    The project finances the Borrower's expenditures to develop their lead product as a treatment for Long Covid. The financed R&D will be carried out in France.

    The loan will finance research, development and innovation (RDI) investments to further advance the promoter's product pipeline.

    Additionality and Impact

    The EIB will support the promoter, an early-stage innovative biotechnology SME specialised in neurodegenerative and autoimmune diseases to develop potentially the first evidence-based treatment for Long-Covid. The project, if successful, is expected to have significant financial and broader social benefits, in terms of improved health and welfare. While the promoter does not yet have any commercial stage products, the promoter and its staff have long experience bringing innovative products through clinical trials. By supporting the promoter, the EIB enables the generation of European scientific knowledge and acumen, whilst preserving highly skilled employment opportunities. Due to volatility and deterioration of the environment on the capital markets, access to equity financing is limited for innovative but risky companies such as the promoter. The financing structure is adjusted to the investment needs resulting from the R&D and clinical trials carried out by the promoter. The 5 years tenor provides a sufficient time frame for the company to complete the clinical trials and to initiate the first commercial sales. Thanks to the support of InvestEU, the EIB may provide long term financing in the form of venture debt to a highly innovative but high-risk early-stage company with no access to commercial debt. By contributing to extending the cash runway and therefore to de-risking the development plan of the company, the EIB financing is expected to crowd-in third party investors and allow the company to accelerate its development.

    Environmental aspects

    The promoter's investments concern RDI activities to be carried out in existing facilities already authorised for the same purpose. As such, they would therefore not require an environmental impact assessment (EIA) under Directive 2011/92/EU. Full environmental details will be verified during appraisal.

    The promoter is a private company, not operating in the utilities sector and which does not have the status of a contracting authority; thus the project is not covered by the EU directives on procurement. However, the Promoter's procurement procedures are expected to be in line with EIB guidelines for private sector projects. The EIB's services will verify details during the project due diligence.

    Under appraisal
    21 December 2022
    29 December 2022
    Related projects
    Link to source


    Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
    They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).


    Environmental and Social Data Sheet (ESDS) - POST-ACUTE SEQUELAE COVID RDI (IEU TI)
    Publication Date
    8 Nov 2023
    Document language
    Main Topic
    Document Number
    Document Focus
    Environmental Information
    Project Number
    Publicly available
    Download now

    News & Stories

    General enquiries and comments

    The EIB is committed to open communication and encourages constructive stakeholder input regarding its activities.
    Enquiries and comments concerning the EIB’s involvement in a project or the financing facilities, activities, organisation and objectives of the EIB, can be sent to the EIB Infodesk.
    Alternatively, the EIB can be contacted through its external offices.
    Queries regarding details of a specific project, in particular when it is under appraisal by the EIB, should preferably be addressed directly to project promoters.

    Media enquiries

    Media-related enquiries can be addressed to the EIB Press Office. Please also visit our Media information section.

    Complaints mechanism

    Any complaint regarding alleged maladministration can be lodged via the EIB Complaints Mechanism. The European Ombudsman acts as an independent external accountability mechanism of the EIB.

    Zero tolerance against fraud and corruption

    The EIB has a zero tolerance policy on fraud or corruption. To report allegations of fraud and corruption relating to EIB-financed projects, please contact the Fraud and Investigation division. All complaints will be treated as strictly confidential and handled in line with the EIB investigation procedures and the Anti-Fraud Policy.

    Related publications